Weight Loss Peptides
Fat Loss & Metabolic Peptide Guide
Non-GLP-1 peptides studied for fat metabolism
This page groups the non-GLP-1 peptides most often discussed for fat loss: tesamorelin and ipamorelin, which raise growth hormone; AOD-9604, a fragment of growth hormone; and MOTS-c, a mitochondrial peptide studied in mice for its effects on metabolism. Their evidence differs widely. Tesamorelin is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it isn't for weight loss. AOD-9604 failed its human obesity trials, and neither MOTS-c nor ipamorelin has been tested for fat loss in people. Semaglutide and tirzepatide, the peptides with by far the strongest weight-loss evidence, are FDA-approved prescription medicines and have their own pages.
Key Benefits
Mechanism of Action
These compounds act on different pathways, and most of the mechanism data come from animal or lab studies. Tesamorelin is a GHRH analog and ipamorelin is a growth hormone secretagogue; both raise growth hormone, which promotes lipolysis (fat breakdown). In tesamorelin's Phase 3 trials, that showed up as less visceral (deep abdominal) fat with no change in body weight. AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) designed to keep the hormone's fat-breakdown signal without its effects on growth. It reduced fat in rodents, but in human oral trials it didn't produce meaningful weight loss, and those trials found no significant change in IGF-1. MOTS-c is a peptide encoded in mitochondrial DNA that activates AMPK, an enzyme that senses cellular energy. In mice it improved insulin sensitivity and exercise capacity; as of October 2026, no peer-reviewed study has given native MOTS-c to people. No trial has tested any combination of these compounds.
Dosing Guidelines
Typical Dose
Varies by peptide (see notes)
Frequency
Varies by peptide
Duration
4-26 weeks, by peptide
Note: These figures come from drug labels, trials, user reports and vendor guidance, labeled by source; none is a recommendation. Tesamorelin: the label dose for adults with HIV-associated lipodystrophy is 2 mg of the original Egrifta (used in the Phase 3 trials) or 1.28 mg of Egrifta WR, by subcutaneous injection once daily, and the formulations aren't interchangeable mg-for-mg; users commonly report 1-2 mg nightly for 12-26 weeks. Ipamorelin: vendor guidance lists 200-300 mcg two to three times daily, while many users describe one bedtime dose of 100-300 mcg; the only human trials gave it by IV. AOD-9604: users most often report 300 mcg (range 300-500 mcg) by subcutaneous injection once daily for about 12 weeks; the human trials used oral doses of 0.25-1 mg daily, and no human trial has tested injected AOD-9604. MOTS-c: no human dose-finding study exists; users commonly report 10-15 mg per week split into two or three injections (for example, 5 mg two or three times weekly) for 4-8 weeks. Morning fasted dosing is a community and vendor practice for AOD-9604, and empty-stomach bedtime dosing is common for ipamorelin; no trial has tested either timing, and the tesamorelin label sets no fasting or time-of-day rule. As of October 2026, WADA prohibits all four compounds at all times.
Research & Studies
Overview of peptides studied for fat metabolism, with their mechanisms, reported protocols and how the evidence for each compares.
Read Full ResearchThe FDA-approved GHRH analog for excess abdominal fat in HIV-associated lipodystrophy. Its label says it isn't indicated for weight loss.
Read Full ResearchMOTS-c and SS-31, two peptides that act on mitochondria. MOTS-c data come mostly from mice; SS-31 is FDA-approved only for Barth syndrome.
Read Full ResearchHow these growth hormone secretagogues raise growth hormone. No human trial has measured fat loss with either one.
Read Full ResearchAn FDA-approved prescription GLP-1 medicine for weight management (Wegovy), backed by far more human trial data than any compound above.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- - Water retention, mostly early on (user reports with tesamorelin and ipamorelin)
- - Injection-site reactions (25% vs 14% on placebo with tesamorelin in trials; itchy welts commonly reported by MOTS-c users)
- - Joint pain (13%) and muscle aches (6%) with tesamorelin in trials
- - Higher blood sugar: more diabetes-range HbA1c on tesamorelin than placebo (5% vs 1%), and more high blood sugar on ipamorelin than placebo in a Phase 2 trial
- - IGF-1 above the normal range in 47% of tesamorelin users at 26 weeks (the label advises monitoring)
- - Tingling or numbness in the hands and feet (tesamorelin trials; ipamorelin user reports)
- - Headache, diarrhea and flatulence (AOD-9604 oral and IV trials)
- - Allergic-type reactions, including a few secondhand forum reports of throat swelling with MOTS-c (unverified)
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
Weight Loss Peptides + Tesamorelin + AOD-9604
A pairing that appears in vendor and forum guides. Tesamorelin is FDA-approved only for excess abdominal fat in HIV-associated lipodystrophy, AOD-9604 failed its human obesity trials, and no study has tested the two together.
Shop this stackWeight Loss Peptides + Ipamorelin + CJC-1295
Commonly combined by users, usually with the no-DAC form of CJC-1295 (Mod GRF 1-29) at bedtime, because the two raise growth hormone through different receptors. Small 2006 studies showed CJC-1295 kept growth hormone and IGF-1 raised for days in healthy adults, but no trial has tested the combination or measured fat loss.
Shop this stackWeight Loss Peptides + BPC-157
Some users add it during a calorie deficit for gut comfort or recovery. That use rests on rodent data: BPC-157 has only three small uncontrolled human pilots and hasn't been studied for fat loss.
Shop this stackFrequently Asked Questions
Which weight loss peptide has the best evidence?
Semaglutide and tirzepatide, by a wide margin. Both are FDA-approved prescription medicines for weight management (Wegovy and Zepbound), and in large Phase 3 trials adults with obesity lost about 15-21% of body weight on average at the top labeled doses. Research-use-only versions aren't equivalent to the approved products, and as of October 2026 FDA has warned sellers of GLP-1s labeled "for research purposes". Among the compounds on this page, tesamorelin has the strongest human data, but for one narrow use: two 26-week Phase 3 trials in adults with HIV-associated lipodystrophy found visceral fat fell 14-18% (vs -2% to +2% on placebo) with no change in body weight, and its label says it isn't indicated for weight loss.
Do I need to diet while using fat loss peptides?
There's little evidence either way. AOD-9604's largest human trial paired it with a supervised diet and exercise program for 24 weeks and still found no meaningful weight loss compared with placebo, and tesamorelin's trials showed no change in body weight. Community guides commonly pair these compounds with a moderate calorie deficit and training, but that pairing hasn't been tested as a protocol. A healthcare professional is the right person to advise on any weight-loss plan.
How long until I see fat loss results?
No study has measured a fat-loss timeline for ipamorelin, AOD-9604 or MOTS-c. User reports vary widely, and many AOD-9604 users describe little or no measurable change after 12 weeks. In tesamorelin's Phase 3 trials, visceral fat was measured at 26 weeks, and it rose again within 26 weeks of stopping.
Will fat loss peptides cause muscle loss?
The data can't answer that. AOD-9604 and MOTS-c have no human body-composition data, and no trial has measured muscle or fat with ipamorelin or CJC-1295 in people trying to lose fat. Tesamorelin's trials looked at visceral fat in adults with HIV-associated lipodystrophy, not at fat loss in general. Claims that these peptides burn fat without any muscle loss come from vendor and community guides, not from trials.
You might also like
These peptides share research keywords or protocol overlap with Weight Loss Peptides.
AOD-9604
Growth hormone fragment studied for fat metabolism
Ready to Purchase Weight Loss Peptides?
Get pharmaceutical-grade Weight Loss Peptides from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy Weight Loss Peptides Now